H. Lundbeck A/S (HLBBF)
| Market Cap | 5.46B |
| Revenue (ttm) | 3.33B |
| Net Income (ttm) | 476.54M |
| Shares Out | n/a |
| EPS (ttm) | 0.48 |
| PE Ratio | 11.46 |
| Forward PE | 6.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176 |
| Average Volume | 494 |
| Open | 5.35 |
| Previous Close | n/a |
| Day's Range | 5.35 - 5.35 |
| 52-Week Range | 4.42 - 7.50 |
| Beta | 0.28 |
| RSI | 47.40 |
| Earnings Date | Aug 20, 2025 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Full Company ProfileFinancial Performance
In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.
Financial numbers in DKK Financial StatementsNews
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant reduction...
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reduct...
Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers
Lundbeck’s strong Q1, undervaluation, and pipeline potential offset policy and clinical risks, with upside tied to key catalysts. Find out why HLBBF stock is a buy.
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with successful clinical trials.
Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Monday. Shares of NVIDIA Corporation (NASDAQ: NVDA) rose during Monday’s trading session. A government-backed think tank...
Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record
Lundbeck announced Monday it would buy Longboard Pharmaceuticals in a $2.6 billion deal that sent Longboard stock to a record high.
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion
Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?
H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. ... Full story available on Benzinga.com
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply in today's pre-market trading . Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2....
Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal
Danish pharmaceutical company H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc in a deal with an equity value of $2.6 billion.